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Introduction
The blood-brain barrier (BBB) is formed by brain capillary endothelial cells and serves to stabilize the homeostasis of the CNS. The barrier is formed by tight junction proteins, which restrict passage of blood components through endothelial cells of cerebral capillaries (Hawkins & Davis, 2005) . Several studies have shown that tight junction proteins, such as occludin and zonula occludens-1 (ZO-1), are essential for maintaining the BBB integrity and that a reduction of these proteins results in alterations in tight junction structure and BBB permeability and formation of cerebral oedema (Kirk et al. 2003; Bauer et al. 2010) . Occludin, as an integral membrane protein, regulates paracellular permeability through regulation of tight junction integrity (Furuse et al. 1993; Hirase et al. 1997; Lacaz-Vieira et al. 1999) . Zonula occludens-1, as a peripheral membrane phosphoprotein, is located on the cytoplasmic side of all tight junctions (Willott et al. 1992 (Willott et al. , 1993 Jesaitis & Goodenough, 1994) and binds to other tight junction proteins, such as occludin, and the actin cytoskeleton (João & Arana-Chavez, 2004 ). This interaction of tight junctions with the actin cytoskeleton is probably essential for the protection, regulation and function of the tight junction, because disconnection of ZO-1 from the junctional complex is often associated with increased permeability (Shen et al. 2008) .
Several experimental studies have indicated that hypoxia and hypoxia-reoxygenation decrease expression of occludin and ZO-1, which leads to disruption of the BBB, increased cerebrovascular permeability and formation of brain oedema (Abbruscato & Davis, 1999; Fischer et al. 1999 Fischer et al. , 2002 Mark & Davis, 2002; Witt et al. 2003; Bauer et al. 2010) .
Ghrelin, a 28-amino-acid peptide hormone, has a variety of effects in the CNS (Kojima et al. 1999; van der Lely et al. 2004) , including neuroprotective, anti-apoptotic and anti-inflammatory properties (Granado et al. 2005; Miao et al. 2007 ). Moreover, our previous studies showed that ghrelin considerably reduced brain oedema, along with decreasing tumour necrosis factor-α (TNF-α) levels and vascular endothelial growth factor (VEGF) expression in a systemic hypoxia model in rats (Hossienzadeh et al. 2013; Mohaddes et al. 2015 ). An earlier study has also reported that administration of ghrelin increases the expression of occludin and ZO-1 in a traumatic spinal cord injury model (Lee et al. 2014 ).
Considering the above-mentioned facts about occludin and ZO-1, the present study was designed to evaluate the effect of ghrelin on occludin and ZO-1 expression in the hypoxic brain.
Methods

Ethical approval
The study was approved by the research and ethics committee of Tabriz University of Medical Sciences in Iran (no. 89/4-13/11). All experiments were performed in conformity with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 23-86; revised 1996) .
Animals and experimental groups
Adult male Wistar rats (250 ± 30 g, 5 months old) were obtained from Tabriz University of Medical Sciences laboratory animal house. All rats were housed in standard cages in an environment with controlled temperature (22-24°C), humidity (40-60%) and photoperiod (12 h-12 h light-dark cycle). Food and water were available ad libitum.
Thirty-six animals were randomly divided into the following six (n = 6 per group) experimental groups: (i) acute control (C2), in which animals were placed in room air (21% O 2 ) for 2 days; (ii) acute hypoxia and saline (AH), in which animals were exposed to 10-11% O 2 received saline for 2 days; (iii) acute hypoxia and ghrelin (AH+G), in which animals were exposed to 10-11% O 2 and received ghrelin for 2 days; (iv) chronic control (C10), in which animals were placed in room air (21% O 2 ) for 10 days; (v) chronic hypoxia and saline (CH), in which animals were exposed to 10-11% O 2 and received saline for 10 days; and (vi) chronic hypoxia and ghrelin (CH+G), in which animals were exposed to 10-11% O 2 and received ghrelin for 10 days.
Control and hypoxia groups received saline (1 ml kg −1 day −1 , I.P.) or ghrelin (Innovagen AB, Lund, Sweden) at a dose of 80 μg kg −1 , I.P., respectively (Hossienzadeh et al. 2013 ).
Induction of normobaric hypoxia
Acute and chronic systemic hypoxia (10-11 % O 2 ) was induced in a hypoxic chamber (GO2Altitude R , Biomedtech Australia Pty Ltd, State Victoria, Australia). Acute and chronic hypoxic groups were kept in the chamber all the time for 2 and 10 days respectively, except for cleaning the cages and daily injections.
Western blot analysis of ZO-1 and occludin
For the Western blot study, rats (n = 6) were deeply anaesthetized by I.P. injection of sodium pentobarbital (100 mg kg −1 ) and decapitated, and their brains were removed and frozen in liquid nitrogen. Brain samples were homogenized in 1 ml of lysis buffer [0.5% Nonidet P-40, 1% Triton X-100, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 0/1% SDS, 1 mM EGTA, 2 mM phenylmethylsulphonyl fluoride and 1% protease inhibitor cocktail] and centrifuged at 18,000g for 30 min. The protein concentration in the homogenate was determined by measuring the absorbance of the lysates at 280 nm (Mohaddes et al. 2015) . Equal amounts of samples (20 μg proteins) were electrophoretically separated on 10% SDS-PAGE gels for ZO-1 and 12% SDS-PAGE gels for occludin. The proteins were transferred onto polyvinylidene difluoride membranes. Subsequently, G. Mohaddes and others membranes were blocked for 1 h in 5% milk and incubated for 90 min or 1 h at room temperature with primary antibodies against ZO-1 (Invitrogen, Thermo Fisher Scientific, Rockford, IL, USA; catalogue no. 61-7300), occludin (Invitrogen; catalogue no. 71-1500) and β-actin (Abcam, Cambridge, MA, USA; catalogue no. 8227), diluted 1:1000, 1:5000 and 1:3000 in blocking solution, respectively. After washing, incubation with horseradish peroxidase-conjugated secondary antibody diluted 1:3000 in 5% milk for 1 h at room temperature and further washing, the blots were visualized with the enhanced chemiluminescence (ECL) detection kit (GE healthcare, Chicago, IL, USA)/ for 1 min and exposed to hyperfilm for 30 s to 5 min. Finally, the developed films were scanned, and the density of the immunoreactive bands was determined using ImageJ software (available at imagej.nih.gov/ij/index.html) and normalized to the bands of the internal control (β-actin).
Statistical analysis SPSS 17.0 software (Armonk, New York, USA) was used for statistical comparisons of data. Data are presented as means ± SD. Differences in the image density were compared by the non-parametric Kruskal-Wallis test followed by the Mann-Whitney U test. A value of P < 0.05 was considered statistically significant.
Results
Effects of acute systemic hypoxia and ghrelin on occludin expression in the hypoxic brain
Western blot analysis showed that acute systemic hypoxia significantly decreased occludin expression compared with the acute control group (0.51 ± 0.23 versus 1.0 ± 0.0, P < 0.001), and ghrelin administration had no significant effect on occludin in the acute hypoxic group (0.71 ± 0.28 versus 0.51 ± 0.23, P > 0.05). In addition, treatment with ghrelin did not significantly change occludin protein expression in comparison with the acute control group (0.71 ± 0.28 versus 1.0 ± 0.0, P > 0.05; Fig. 1 ).
Effects of chronic systemic hypoxia and ghrelin on occludin expression in the hypoxic brain
Chronic systemic hypoxia significantly decreased occludin expression in comparison with the chronic control group (0.62 ± 0.17 versus 1.0 ± 0.0, P < 0.001), and injection of ghrelin effectively increased occludin expression in comparison with chronic hypoxia group (1.2 ± 0.26 versus 0.62 ± 0.17, P < 0.001). Furthermore, treatment with ghrelin did not significantly change occludin protein expression in comparison with the chronic control group (1.2 ± 0.26 versus 1.0 ± 0.0, P > 0.05; Fig. 2 ).
Effects of acute systemic hypoxia and ghrelin on ZO-1 expression in the hypoxic brain
Western blot analysis revealed that acute hypoxia significantly decreased ZO-1 protein expression in comparison with the acute control group (0.55 ± 0.21 versus 1.0 ± 0.0, P < 0.001). Ghrelin treatment significantly increased ZO-1 expression in the acute hypoxia group (1.024 ± 0.25 versus 0.55 ± 0.21, P < 0.05). In addition, treatment with ghrelin did not significantly change ZO-1 protein expression (1.024 ± 0.25 versus 1.0 ± 0.0, P > 0.05) in comparison with the acute control group (Fig. 3) . There was no significant difference between the control group and acute hypoxia after ghrelin administration group (AH+G). B, occludin expression in the acute control (C2) and acute hypoxia groups that received saline (AH) or ghrelin (AH+G) for 2 days. * * * P < 0.001 versus the control group. Data are shown as the mean ± SD for n = 6 animals per group. the chronic hypoxia group (1.14 ± 0.24 versus 0.56 ± 0.19, P < 0.05). In addition, treatment with ghrelin did not significantly change ZO-1 protein expression (1.14 ± 0.24 versus 1.0 ± 0.0, P > 0.05) in comparison with the chronic control group (Fig. 4) .
Discussion
This study provides evidence that both acute and chronic systemic hypoxia decrease occludin and ZO-1 protein levels in the brain of rats. Tight junction proteins, such as occludin and ZO-1, have an essential role in maintaining BBB integrity (Bauer et al. 2010) , and reduction of these proteins causes alterations in tight junction structure, BBB leakage and formation of cerebral oedema (Kirk et al. 2003) . Reduction of occludin and ZO-1 protein levels occurs in hypoxic conditions and suggests a reasonable explanation for the alterations of BBB function and formation of brain oedema (Kirk et al. 2003; Bauer et al. 2010) .
In the present study, rats were exposed to 10-11% oxygen for 2 or 10 days and a short (10 min) reoxygenation There was a significant difference between the control group and the chronic hypoxia after ghrelin administration group (CH+G). B, occludin expression in the chronic control group (C10) and chronic hypoxia groups that received saline (CH) or ghrelin (CH+G) for 10 days. * * * P < 0.001 versus the control group. ### P < 0.001 versus the CH group. Data are shown as the mean ± SD for n = 6 animals per group.
daily. In these conditions, there was a significant difference in ZO-1 and occludin expression compared with the control groups. Consistent with our findings, Bauer et al. (2010) demonstrated that systemic hypoxia (for 48 h) decreased occludin expression in the brains of mice without having a significant effect on ZO-1 expression. However, several in vitro studies showed that hypoxia also disrupted the continuity of ZO-1 protein and decreased ZO-1 protein expression in cultured endothelial cells (Fischer et al. 2002 (Fischer et al. , 2004 . Another in vitro study also showed that hypoxia disrupted the continuous pericellular distribution of occludin and ZO-1, and 2 h of reoxygenation after hypoxia increased expression of both ZO-1 and occludin (Mark & Davis, 2002) . In contrast, some studies revealed that hypoxia induced no significant changes in protein expression of occludin or ZO-1 in bovine brain microvessel endothelial cells after 6 h exposure to hypoxia (Brown et al. 2003; Brown & Davis, 2005) . These controversies among different studies may have resulted from the in vivo or in vitro conditions, the severity and duration of hypoxic exposure, the existence of a short period of reoxygenation in our model, and the diversity of animals used. There was a significant difference between the control group and the acute hypoxia after ghrelin administration group (AH+G). B, ZO-1 expression in the acute control group (C2) and acute hypoxia groups that received saline (AH) or ghrelin (AH+G) for 2 days. * * * P < 0.001 versus the control group. # P < 0.05 versus the AH group. Data are shown as the mean ± SD for n = 6 animals per groups.
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Although the underlying mechanisms of these observations are unknown, they may be, at least in part, the result of increasing matrix metalloproteinase 9 (MMP9) and VEGF expressions. Hypoxia causes an increase in expression of MMP9, VEGF and TNF-α, which can lead to increased BBB permeability (Bauer et al. 2010; Hossienzadeh et al. 2013; Mohaddes et al. 2015) . Occludin and ZO-1 are susceptible to attack and lysis by MMP9 (Asahi et al. 2001; Yang et al. 2007) . Upregulation of MMP9 occurs in neurons, astrocytes, oligodendrocytes, microglia and endothelial cells following brain injury (Rosenberg, 2009) , especially traumatic brain injury, and systemic hypoxia (Bauer et al. 2010; Higashida et al. 2011) . Some studies have demonstrated that Mmp9 gene knock-out mice experienced less BBB disruption and subsequent formation of brain oedema in response to transient focal ischaemia and traumatic brain injury (Wang et al. 2000; Asahi et al. 2001) .
There is also some evidence that hypoxia increases the paracellular flux across the cell layer via the release of VEGF, which in turn leads to the dislocalization, decreased expression and increased phosphorylation There was a significant difference between the control group and the chronic hypoxia after ghrelin administration group (CH+G). B, ZO-1 expression in the chronic control group (C10) and chronic hypoxia groups that received saline (CH) or ghrelin (CH + G) for 10 days. * * * P < 0.001 versus the control group. # P < 0.05 versus the CH group. Data are shown as the mean ± SD for n = 6 animals per group.
of ZO-1 (Fischer et al. 2002) . Our previous study revealed an increase in VEGF expression in the hypoxic brain (Mohaddes et al. 2015) ; therefore, it seems that hypoxia-induced reduction of the expression of ZO-1 and occludin is mediated in part by increasing VEGF expression. This is in agreement with another study indicating that hypoxia-induced permeability in vitro is mediated by the VEGF-VEGF receptor system in an autocrine manner (Fischer et al. 2002) . By investigating the BBB protective capacity of ghrelin in the present study, we showed, for the first time, that administration of ghrelin effectively increased ZO-1 protein levels in both acute and chronic systemic hypoxia to values comparable to control groups, and ghrelin also increased occludin expression during chronic systemic hypoxia. These findings are in agreement with a recent study showing that ghrelin significantly increased the expression of occludin and ZO-1 in a traumatic spinal cord injury model (Lee et al. 2014) .
In the present study, ghrelin did not significantly influence occludin expression in acute hypoxia. One possible explanation for this finding is that the duration of the treatment with ghrelin or its dose was not sufficient to modulate occludin expression in acute hypoxia. Ghrelin, a brain-gut peptide (Korbonits et al. 2004) , has neuroprotective, anti-inflammatory and anti-oedematous effects (Hossienzadeh et al. 2013) . Ghrelin receptors have been found in various regions of the brain, such as the hypothalamus, pituitary, hippocampus, cerebral cortex and the endothelial cells of the BBB (Pan et al. 2006; Zigman et al. 2006) . Our previous studies showed that ghrelin had an anti-oedematous effect and efficiently inhibited TNF-α protein synthesis and VEGF protein levels in a model of systemic hypoxia (Hossienzadeh et al. 2013; Mohaddes et al. 2015) .
The results of the present research suggest that ghrelin, by increasing occludin and ZO-1 protein expression, maintains the integrity of the BBB in the hypoxic situation. Recent studies have reported that activation of MMP9 and increased TNF-α and VEGF protein levels play important roles in the pathogenesis of the BBB breakdown and brain oedema in hypoxic conditions (Bauer et al. 2010; Hossienzadeh et al. 2013; Mohaddes et al. 2015) . The fact that ghrelin injection reduces the levels of VEGF and TNF-α as well as the activation of MMP9 (Bansal et al. 2010; Lopez et al. 2012; Hossienzadeh et al. 2013; Mohaddes et al. 2015) suggests that the beneficial effect of ghrelin may result, at least in part, from the inhibition of production of these factors and, consequently, the protection of tight junction proteins, such as occludin and ZO-1, from disruption. The underlying molecular mechanisms of the beneficial effects of ghrelin on the BBB are not completely clear in the hypoxic conditions; therefore, further experiments are needed to clarify these mechanisms.
Conclusion
Our study showed that both acute and chronic systemic hypoxia decreased the protein expression of occludin and ZO-1. Ghrelin treatment increased ZO-1 protein expression in both acute and chronic hypoxia; however, ghrelin increased occludin expression only in chronic hypoxia. Ghrelin appears to be a new therapeutic strategy for protection from BBB disruption and treatment of brain oedema in hypoxic conditions.
